AVTE — Aerovate Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $80.54m
- -$23.66m
Annual income statement for Aerovate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 3.33 | 8.89 | 23 | 53.2 | 81.4 |
| Operating Profit | -3.33 | -8.89 | -23 | -53.2 | -81.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.33 | -9.61 | -23 | -51.5 | -75.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.33 | -9.61 | -23 | -51.5 | -75.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.33 | -9.61 | -23 | -51.5 | -75.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.33 | -9.76 | -23 | -51.5 | -75.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.144 | -0.423 | -0.995 | -2.1 | -2.87 |
| Dividends per Share |